The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) and the associated coronavirus disease 2019 (COVID-19) continue to spread throughout the world, causing more than 120 million infections. Several variants of concern (VOCs) have emerged and spread with implications for vaccine efficacy, therapeutic antibody treatments, and possible reinfections. On 17 March 2021, several VOCs were detected, including lineage B.1.1.7, first identified in the UK, B.1.351 in South Africa, Lineage P.1 (B.1.1.28.1) in Brazil, and novel Sub-Lineage A (A.23.1), reported in Uganda, and B.1.525, reported in Nigeria. Here, we describe an 83-year-old man infected with the SARS-CoV-2 P.1 variant after two doses of the BNT162b2 mRNA COVID-19 vaccine.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, Immunity, P.1 variant, Brazilian variant, 【초록키워드】 coronavirus disease, Brazil, Uganda, Efficacy, coronavirus, COVID-19 vaccine, antibody, VoC, B.1.351, variants of concern, Nigeria, Spread, South Africa, infections, B.1.1.28.1, P.1, therapeutic, VOCs, Lineage B.1.1.7, BNT162b2 mRNA, dose, acute respiratory syndrome, A.23.1, B.1.525, implication, reported, the SARS-CoV-2, 【제목키워드】 P.1, B.1.1.28, Man,